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ABSTRACT
Aim To compare early versus delayed intravitreal
betamethasone as an adjuvant in the treatment of
presumed acute postoperative endophthalmitis after
phacoemulsiﬁcation.
Methods Patients with presumed postcataract surgery
endophthalmitis were included in this prospective,
randomised, multicentre study. On admission, patients
received intravitreal vancomycin and ceftazidime, and
were randomly assigned to intravitreal betamethasone
injection (early-IVB) group or no immediate injection
(delayed-IVB) group. After 48 h, a second intravitreal
antibiotic injection associated with intravitreal
betamethasone was given to all patients. In patients
with severe endophthalmitis or clinical deterioration, a
prompt or delayed vitrectomy was performed. The
primary outcome was the proportion of patients
achieving a visual acuity (VA) of 20/40 or better at
12 months. The secondary outcomes were the rate of
delayed vitrectomy and the rate of complications (retinal
detachment and phthisis).
Results Ninety-seven eyes of 97 patients were
included, 45 in the early-IVB group and 52 in the
delayed-IVB group. Overall, 62.9% of patients achieved
a VA ≥20/40 at 1 year. There was no statistically
signiﬁcant difference in the visual outcome between the
two groups at 1 year, whatever their baseline VA or light
perception or hand motion or more (p=0.55 and
p=0.10, respectively). The rates of delayed vitrectomy,
retinal detachment and phthisis bulbi were not
signiﬁcantly different between the two groups (p=0.42,
p=0.37 and p=0.44, respectively).
Conclusions Early intravitreal betamethasone had no
clear advantage versus delayed injection in the
management of presumed postoperative
endophthalmitis.
INTRODUCTION
Postoperative endophthalmitis is a rare but devas-
tating complication of cataract surgery. The man-
agement of postoperative endophthalmitis has been
clariﬁed since 1995 with the endophthalmitis
vitrectomy study (EVS), especially for the indica-
tion of pars plana vitrectomy (PPV) when baseline
visual acuity (VA) is limited to light perception
(LP).1 In this study, the use of corticosteroids was
limited to oral and topical routes. The use of intra-
vitreal corticosteroids in endophthalmitis was ﬁrst
suggested by Peyman in 1974.2 In fact, the host
inﬂammatory reaction, triggered by bacterial
components and toxins, is involved in the alteration
of ocular structures (loss of media transparency and
retinal necrosis) and complications (macular
oedema and retinal detachment) and continues
after bacterial death.3 A recent detailed analysis of
preclinical studies could not provide a ﬁrm conclu-
sion on the efﬁcacy of adjunctive intravitreal injec-
tion (IVI) dexamethasone in experimental
endophthalmitis.4 However, it was shown that the
timing of IVI corticosteroids was critical since the
control of intraocular inﬂammation was better
when IVI dexamethasone was used early in the
course of experimental endophthalmitis.2 5 Several
clinical studies evaluating the yield of intravitreal
corticosteroids as adjunctive therapy in the manage-
ment of postoperative endophthalmitis have been
published, but so far there is no clear evidence to
support the use of IVI corticosteroid injection as an
adjunctive treatment in the management of acute
postoperative endophthalmitis.4 In the present
study, we conducted a prospective multicentre clin-
ical trial to compare the effect of an early intravi-
treal betamethasone injection versus a 48 h delayed
intravitreal betamethasone injection as adjunctive
therapy in the treatment of acute postoperative
endophthalmitis after phacoemulsiﬁcation.
MATERIAL AND METHODS
Patients with presumed postcataract endophthalmi-
tis were included in this prospective study between
1 July 2007 and 31 August 2013 in six French uni-
versity hospitals (Besançon, Dijon, Grenoble,
Nancy, Saint-Etienne and Strasbourg). Most
patients were operated on for cataract in medical
facilities outside the university hospitals where they
were referred. The study followed the Declaration
of Helsinki guidelines for research involving
human subjects and was approved by the local insti-
tutional review board (Comité de Protection des
Personnes, IRB# 2007-003730-42). Protocols for
data collection, sampling procedures, microbio-
logical analysis, intravitreal antibiotics and vitrec-
tomy indications were standardised for the six
centres.
Patient enrolment
Patients were eligible if they presented clinical signs
of endophthalmitis within 30 days after cataract
surgery. The diagnosis of endophthalmitis was made
on clinical features including pain, decreased VA,
diffuse bulbar conjunctival hyperaemia, chemosis,
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inﬂammation of the anterior segment (anterior chamber reaction
including one of the following criteria: ﬂare, cells, hypopyon,
ﬁbrin, cyclitic membrane) and posterior segment inﬂammation
(seen with biomicroscopy or echography). Preoperative and/or
intraoperative antibiotic prophylaxis was not an exclusion criter-
ion. Corticosteroids, whatever the route (systemic, subconjuncti-
val or intravitreal), and endophthalmitis following a surgery
other than cataract extraction were exclusion criteria. Inclusion
and randomisation started after a systematic explanation of the
study and once informed consent had been obtained. A single
masked randomisation was done using sealed envelopes, opened
by caregivers other than the doctors who took the samples and
gave the ﬁrst intravitreal injections.
Intervention
On presentation, an aqueous humour and/or vitreous tap was
performed, followed by an intravitreal injection of vancomycin
(1 mg/0.1 mL, Vancomycin Sandoz, Sandoz, Holzkirchen,
Germany) and ceftazidime (2.25 mg/0.1 mL, Fortum,
GlaxoSmithKline, London, UK). Depending on the randomisa-
tion, an intravitreal injection of betamethasone (0.4 mg/0.1 mL,
Célestène, MSD, White House Station, New Jersey, USA) was
given (early-IVB) or not given (delayed-IVB). Fortiﬁed topical
antibiotics (vancomycin 50 mg/mL and ceftazidime 30 mg/mL)
were given for 3 days and then a combination of tobramycin
and dexamethasone was instilled six times a day and tapered
over the next 4–6 weeks. Cycloplegics were administered as well
for 2–3 weeks. At 48 h, all patients received a second intravitreal
antibiotic injection and an intravitreal injection of betametha-
sone (0.4 mg/0.1 mL). Then a regimen of subconjunctival injec-
tions of betamethasone (4 mg/1 mL)/lidocaine (10 mg/mL,
Lidocaïne, Aguettant, Lyon, France) was added twice a day for
5 days. On admission, a prompt PPV could be performed at the
discretion of the physician, in line with the recommendations of
the EVS (ie, in case of a baseline VA limited to LP). A delayed
vitrectomy was performed after 72 h in case of anatomical or
functional worsening at the discretion of the surgeon.
Microbiology
Intraocular samples were immediately inoculated on conven-
tional media including blood agar, chocolate agar, Sabouraud’s
dextrose agar and brain heart infusion broth (BioMérieux, Marcy
l’Etoile, France) and Gram stains were performed. Bacteria were
identiﬁed and antibiograms were obtained for positive cultures.
A pan-bacterial PCR was carried out when possible.
Follow-up
At baseline, 8 days, 1, 3, 6 and 12 months, a thorough ocular
evaluation was performed including biomicroscopic and fundus
examination. If media clarity did not allow access to the fundus,
an ultrasound examination was performed. VA was measured
using a Snellen chart at baseline and at each follow-up visit. If a
patient was unable to read, VA was graded as counting ﬁngers at
1 m (CF), hand motions (HM) or LP. VA was converted to the
logarithm of the minimum angle of resolution (logMAR) for
statistical analysis. The primary outcome was the proportion of
patients achieving at least 20/40 (ie, logMAR+0.3) at
12 months. The secondary outcomes were the rate of delayed
vitrectomy and the rate of complications in each group (retinal
detachment and phthisis).
Statistical analysis
Statistical analysis was carried out using SAS (V.9.2, SAS
Institute, Cary, North Carolina, USA, 2008). According to
Holladay,6 VA equal to CF and HM corresponds to logMAR 2
and logMAR 3, respectively. VA limited to LP corresponds to an
evaluation of a stimulus and cannot be considered as a quantita-
tive variable, thus requiring a speciﬁc study of this subgroup.
Quantitative data were expressed as median (IQR) because the
distribution of continuous variables was non-normal. The pro-
portions were compared using a Fisher exact test for categorical
variables and a Mann–Whitney test for quantitative variables.
A logistic regression analysis was used to estimate the odd ratios
with 95% CIs to determine factors associated with the primary
end point (ﬁnal VA ≥20/40). The threshold for statistical signiﬁ-
cance was set at 5% and the tests were two-tailed.
RESULTS
A total of 97 eyes of 97 patients were included, 45 eyes in the
early-IVB group and 52 in the delayed-IVB group (ﬁgure 1).
The patients’ baseline characteristics are displayed in table 1.
There was no signiﬁcant difference between the two groups
except for baseline VA and the rate of posterior capsular rupture.
Overall, 38.1% (n=37) of the cases received a preoperative or
intraoperative antibiotic prophylaxis, either intracameral injec-
tion of cefuroxime or topical ﬂuoroquinolones. The microbio-
logical analysis modalities included vitreous biopsies in 78.3%
(n=76) and aqueous humour taps in 35.0% (n=34), which were
culture-positive in 60.5% (n=46) and 32.4% (n=11), respect-
ively. Overall bacterial identiﬁcation was obtained in 57.7%
(n=56). Pan-bacterial PCR was performed in 62.8% (n=61) and
was positive in 39.3% (n=24). The microbiological results are
displayed in table 2.
Overall, 62.9% of patients achieved a VA ≥20/40 at 1 year.
Prompt vitrectomy was performed in 24.4% (n=11) in the
early-IVB group and in 34.6% (n=18) in the delayed-IVB group
(p=0.47). In the subgroup of patients with LP at baseline
(n=46), 17 patients were in the early-IVB group and 29 in the
delayed-IVB group. Prompt vitrectomy was performed in 41.2%
in the early-IVB group (n=7) and in 55.2% in the delayed-IVB
group (n=16; p=0.54). For the primary outcome, 41.2% of
patients in the early-IVB group (n=7) achieved a VA ≥20/40 at
12 months and 51.7% in the delayed-IVB group (n=15;
p=0.55; ﬁgure 2A).
In the subgroup of patients with a baseline VA at least equal
to HM (n=51), 28 patients were in the early-IVB group and 23
in the delayed-IVB group. Prompt vitrectomy was performed in
14.3% in the early-IVB group (n=4) and in 8.7% in the
delayed-IVB group (n=2; p=0.68). For the primary outcome,
85.7% of patients in the early-IVB group (n=24) achieved 20/
40 at 12 months and 65.2% in the delayed-IVB group (n=15;
p=0.11; ﬁgure 2B). To overcome the signiﬁcant difference of
baseline VA, the gain of VA adjusted on the baseline VA was ana-
lysed and was not signiﬁcantly different between the two groups
at 12 months (1.51±0.19 logMAR in the early-IVB group vs
1.62±0.16 logMAR in the delayed-IVB group; p=0.66).
However, at 1 month the gain in VA was better in the early-IVB
group than in the delayed-IVB group (1.65±0.15 logMAR vs
1.2±0.15 logMAR; p=0.03; ﬁgure 2C).
For the secondary outcomes, the rate of delayed vitrectomy
was 20.0% in the early-IVB group (n=9) versus 13.5% in the
delayed-IVB group (n=7; p=0.42). The rate of retinal detach-
ment was 5.1% (n=5) for the whole series, 2.2% in the
early-IVB group (n=1) versus 7.7% in the delayed-IVB group
(n=4; p=0.37). Phthisis bulbi was observed in 7.2% of patients
(n=7), two in the early-IVB group and ﬁve in the delayed-IVB
group (p=0.44). All cases were related to poor prognosis bac-
teria with severe presentation at baseline, including one case of
Koehrer P, et al. Br J Ophthalmol 2016;100:1076–1080. doi:10.1136/bjophthalmol-2015-307063 1077
Clinical science
group.bmj.com on February 5, 2017 - Published by http://bjo.bmj.com/Downloaded from 
Haemophilus inﬂuenzae, three streptococci and three
Staphylococcus aureus.
In univariate analysis, early adjunctive intravitreal betametha-
sone was not signiﬁcantly associated with the primary outcome
(p=0.34). Most severe strains (S. aureus or Streptococcus) and
delayed vitrectomy were signiﬁcantly associated with a ﬁnal VA
below 20/40 (p=0.003 and p=0.002, respectively). A longer
time to presentation was positively associated with the primary
end point (p=0.03). In a logistic regression analysis including
all these factors, none was statistically signiﬁcant.
DISCUSSION
In this study, we aimed to compare the adjunctive role of an
early versus a delayed intravitreal betamethasone injection in the
management of presumed postcataract endophthalmitis. We
found that overall the percentage of patients reaching a VA ≥20/
40 at 1 year (the primary outcome) was not statistically different
between the two groups. When differentiating a baseline VA
limited to LP versus HM or more, we reached the same conclu-
sion. We only found a statistical difference at 1 month with a
better gain of VA in patients with a baseline VA equal to HM
who had an early IVB. The rates of delayed vitrectomy, retinal
detachment and phthisis (the secondary outcomes) were not sig-
niﬁcantly different between the early-IVB and delayed-IVB
groups.
Indeed, the adjunctive use of intravitreal corticosteroids in
postoperative endophthalmitis remains controversial.4 In fact,
three comparative retrospective case series gathering a total of
371 cases of postcataract endophthalmitis showed no advantage
of intravitreal corticosteroids—neither prednisolone7 nor dexa-
methasone.8 One of them reported even worse outcomes with
intravitreal dexamethasone.9 Three randomised controlled
studies comparing the effect of IVI dexamethasone versus
placebo as an adjuvant in the treatment of postcataract
endophthalmitis were published.10–12 Gan and Albrecht could
not ﬁnd a signiﬁcant statistical difference between the two
groups in visual outcomes over the short term10 or the long
term at 1 year.11 The most recent one is an interim safety ana-
lysis on 81 cases with a follow-up of 1 year, and the ﬁnal results
will be reported later.12
In our series, the baseline presentation was more severe
(47.5% of patients having LP on admission) than reported by
other groups: 19.0% for Lindstedt,12 26.0% in the EVS1 and
32% in the Friends group.13 Moreover, the rate of complicated
cataract surgery, which could impact visual recovery, was higher
in the present study (15.5%) than in the EVS (11.7%). Our
microbiological ﬁndings are in accordance with the literature
with a large predominance of Gram-positive organisms, mainly
coagulase-negative staphylococci.12 The rate of microorganism
identiﬁcation (57.7%) is in the low range of recent series.12 14
However, the yield of the PCRs in this series was rather low
when compared with previous reports.15 This is mainly due to
some technical differences between centres. The virulence of
isolated bacteria was associated with a poor VA, which has
already been reported.13 Surprisingly, a longer time to presenta-
tion was associated with a better ﬁnal prognosis; this could be
Figure 1 Flow chart of the study.
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related to less virulent microorganisms leading to less severe
symptoms alerting the patient and thus retarding their referral.
At 12 months, overall 62.9% of our patients achieved a ﬁnal
VA ≥20/40, which compares favourably with the three previ-
ously cited series, 70%,12 53%1 and 45%.13 In the subgroup
with baseline LP, 50% of patients achieved a VA ≥20/40, and we
did not observe a statistical difference between an early or a
delayed-IVI betamethasone injection. It should be noted that in
these patients only 71.7% (n=33) had an early vitrectomy.
Therefore, the recommendations of the EVS were not strictly
followed by the investigators.
In the subgroup of patients with baseline VA at least equal to
HM, 76.4% of patients achieved 20/40 at 12 months compared
with 81.0% in the most recent series.12 We found a statistically
better gain in VA at 1 month only in the early-IVB group, but
this difference was not sustained over time.
When considering our secondary outcomes, the rates of
retinal detachment (5.1%) and phthisis (7.2%) are in accord-
ance with the literature: 7% and 8%.13
In human trials, the most thoroughly studied intravitreal cor-
ticosteroid is dexamethasone. However, the commercially avail-
able form of dexamethasone used for injection in our country
contains sulﬁtes and paraben. We were concerned by the potential
toxicity of these agents, as mentioned by Gan et al,11 and this
potential hazard led to ending their study prematurely. This con-
servative approach was shared by other authors.12 Since their pub-
lication, we have used only intravitreal betamethasone in clinical
practice, which does not have these compounds in the commer-
cially available preparation. We acknowledge that data on intravi-
treal betamethasone are scarce. However, a study undertaken in
rats did not ﬁnd an elevation of oxidative stress markers after intra-
vitreal injection of a low dose of betamethasone.16
We acknowledge several limitations to this study. First, ran-
domisation should have been stratiﬁed on baseline VA to
warrant a fair comparison of the two groups. Second, EVS
recommendations concerning prompt vitrectomy in patients
with baseline LP were not strictly followed by all investigators.
Third, the power of our trial was low, which is a weakness of
our study. We calculated that a sample size allowing detection of
a 15% difference for the proportion of patients achieving 20/40
with 80% power using a signiﬁcance level of 0.05 would be 260
patients. With 97 patients, the power of our trial was only 45%,
which was superior to the 25% mentioned by a recent study,10
but certainly insufﬁcient to draw ﬁrm conclusions. Actually,
since July 2012, the widespread use in France of a commercially
available, almost ready-to-use intracameral cefuroxime prepar-
ation has resulted in a dramatic decrease of postoperative
endophthalmitis, thus leading to problems recruiting patients.
In conclusion, the results reported herein show the safety of
an early intravitreal betamethasone injection. However, we were
unable to detect a clear difference for visual recovery between
early and delayed intravitreal betamethasone injection. Further
studies are mandatory to determine the best timing for these
injections.
Table 1 Baseline characteristics of the patients included in the trial evaluating early versus delayed IVB as an adjuvant in the treatment of
presumed postoperative endophthalmitis
Early IVB (45) Delayed IVB (52) Total (97) p Value
Age (years) 75 (68–82) 75 (67–83) 75 (67–82) 0.361
Gender (male) n (%) 18 (40.0) 27 (51.9) 45 (46.4) 0.308
Diabetes mellitus
n (%) Yes
4 (8.9) 11 (21.2) 15 (15.5) 0.158
Onset of symptoms (days) 4.0 (2.0–5.0) 4.0 (2.0–7.0) 4.0 (2.0–6.0) 0.652
Time to presentation (days) 5.0 (4.0–5.0) 5.5 (4.0–9.0) 5.0 (4.0–8.0) 0.174
Posterior capsular rupture
n (%) Yes
3 (6.7) 12 (23.1) 15 (15.5) 0.046
Pain
n (%) Yes
28 (62.2) 29 (55.7) 57 (58.8) 0.542
Visual acuity loss
n (%) Yes
41 (91.1) 47 (90.4) 88 (90.8) 0.999
Baseline visual acuity n (%)
≥20/200 14 (31.1) 3 (5.8) 17 (17.5) 0.001
Count fingers 3 (6.7) 7 (13.5) 10 (10.3) 0.331
Hand motion 11 (24.4) 13 (25.0) 24 (24.7) 0.999
Light perception 17 (37.8) 29 (55.7) 46 (47.5) 0.103
Redness
n (%) Yes
33 (73.3) 32 (61.6) 65 (67.0) 0.280
Chemosis
n (%) Yes
9 (20.0) 8 (15.4) 17 (17.5) 0.600
Corneal oedema
n (%)Yes
18 (40.0) 23 (44.2) 41 (42.2) 0.686
Corneal leakage
n (%) Yes
0 (0.0) 1 (1.9) 1 (0.01) 0.942
Hypopyon
n (%) Yes
25 (55.6) 37 (71.5) 62 (63.9) 0.139
Red reflex loss
n (%) Yes
18 (40.0) 22 (42.3) 40 (41.2) 0.839
Intraocular pressure (mm Hg) 14.0 (10.0–19.0) 15.5 (12.5–23.5) 15.0 (11.0–22.0) 0.210
Statistically significant values are given in bold.
IVB, intravitreal betamethasone.
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